Evidence map›Paper›PMID 14684573›Full record

Trial reportGut2004

Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series.

W Fischbach, M-E Goebeler-Kolve, B Dragosics, A Greiner, M Stolte

Open access · bronzeAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gut, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 4 pooled it
21.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 4 syntheses or guidelines pooled it, 347 citations in OpenAlex.

  1. Effectiveness ofWorld journal of gastroenterology · 2023
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Helicobacter pylori and gastroduodenal ulcer disease.Deutsches Arzteblatt international · 2009
    Guideline
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. [Gastrointestinal mucosa-associated lymphoma].Innere Medizin (Heidelberg, Germany) · 2024
    Article
  16. Helicobacter pylori infection.Nature reviews. Disease primers · 2023
    Review
  17. Article
  18. Review
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

W FischbachDepartment of Internal Medicine, Klinikum Aschaffenburg, Aschaffenburg, Germany. wolfgang.fischbach@klinikum-aschaffenburg.de
M-E Goebeler-Kolve
B Dragosics
A Greiner
M Stolte
University of Würzburg · DEBayreuth Medical Center · DEGesundheitszentrum Oberndorf · ATKlinikum Aschaffenburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHelicobacter pylori plays a decisive role in the pathogenesis of gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT), and eradication therapy has become a widely accepted initial treatment of stage I disease.

objectiveTo determine the long term outcome of patients undergoing exclusive H pylori eradication therapy.

designA prospective series of patients with newly diagnosed marginal zone B cell lymphoma of MALT.

settingMulticentre study in Germany and Austria. PATIENTS: Ninety five patients; 90 of these (five lost to follow up) with a mean age of 54.3 (27-85) years were followed up for at least 12 months.

interventionComplete staging work up revealing stage I disease and H pylori infection. Patients received triple therapy (OMC: omeprazole 20 mg twice daily, metronidazole 400 mg twice daily, and clarithromycin 250 mg twice daily; or OAC: omeprazole 20 mg twice daily, amoxycillin 1000 mg twice daily, and clarithromycin 500 twice daily) for one week.

resultsMedian follow up was 44.6 (12-89) months. H pylori was successfully eradicated in 88 patients (98%); in two patients eradication therapy failed. Long term outcome was characterised by complete regression of lymphoma in 56 patients (62%), minimal residual disease in 17 patients (18%), partial remission in 11 patients (12%), no change in four patients (4%), and progressive disease in two patients (2%). Four patients with complete remission relapsed after 6, 8, 8, and 15 months, one revealing reinfection by H pylori. Regression rate was higher in stage I1 disease compared with stage I2, as diagnosed by endoscopic ultrasound.

conclusionThe majority of patients with low grade gastric MALT lymphoma treated by exclusive H pylori eradication have a favourable long term outcome, offering a real chance of cure.

Indexed as

Helicobacter pyloriAdultAgedAged, 80 and overAmoxicillinAnti-Infective AgentsClarithromycinDrug Therapy, CombinationFemaleFollow-Up StudiesHelicobacter InfectionsHumansLymphoma, B-Cell, Marginal ZoneMaleMetronidazoleMiddle AgedAmoxicillinAnti-Infective AgentsClarithromycinMetronidazoleOmeprazole

Identifiers

PMID14684573
PMCPMC1773912
OpenAlexW1988021144

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.